Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Information
- Disease name
- Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT01697267 | Completed | Phase 3 | Rituximab Vasculitis Maintenance Study | April 2013 | November 21, 2019 |
| NCT05988021 | Completed | Phase 1 | A Study in Healthy Volunteers to Evaluate the Pharmacokinetic Food Effect and Cardiac Safety of CCX168 | December 3, 2015 | May 25, 2016 |
| NCT05988008 | Completed | Phase 1 | A Study of CCX168 in Japanese and Caucasian Healthy Adult Males | October 23, 2017 | September 20, 2018 |
| NCT06004960 | Completed | Phase 1 | A Study to Assess the Mass Balance Recovery (Absorption, Distribution, Metabolism and Excretion) of [14C]CCX168 in Healthy Participants | October 20, 2014 | December 5, 2014 |
| NCT06004947 | Completed | Phase 1 | A Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of CCX168 With Concomitant Medications | January 14, 2016 | June 10, 2016 |
| NCT04413149 | Completed | Anti-neutrophil Cytoplasmic Antibody in Interstitial Lung Disease. | April 1, 2014 | April 1, 2020 | |
| NCT04871191 | Not yet recruiting | Phase 2 | Study of Salvage Therapy to Treat Patients With Granulomatosis With Polyangiitis | March 2023 | January 2027 |
| NCT06350110 | Not yet recruiting | Phase 1/Phase 2 | Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE) | November 10, 2024 | December 28, 2025 |
| NCT06226662 | Not yet recruiting | Phase 2 | Study of NM8074 in Patients With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (AAV) | June 2025 | September 2027 |
| NCT06379646 | Not yet recruiting | N/A | An Clinical Study of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune Disease | April 22, 2024 | April 21, 2026 |
| NCT05969522 | Recruiting | Phase 4 | Stratified Therapy on Pediatric AAGN | January 1, 2023 | December 31, 2025 |
| NCT03323476 | Recruiting | Phase 3 | Maintaining or Stopping Immunosuppressive Therapy in Patients With ANCA Vasculitis and End-stage Renal Disease | February 2, 2018 | March 2031 |
| NCT05732402 | Recruiting | Phase 1/Phase 2 | An Open-label Study of Povetacicept (ALPN-303) in Autoimmune Kidney Diseases | March 15, 2023 | January 2026 |
| NCT06056921 | Recruiting | Phase 1 | Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease | August 31, 2023 | August 31, 2026 |
| NCT06294236 | Recruiting | Phase 1 | Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM) | April 29, 2024 | March 2028 |
| NCT06316076 | Recruiting | Phase 1 | Safety and Efficacy Study of CD19-CAR-DNT Cells in Autoimmune Diseases | October 30, 2023 | June 2026 |
| NCT02749292 | Terminated | Phase 4 | Maintenance of ANCA Vasculitis Remission by Intermittent Rituximab Dosing | June 2016 | January 31, 2022 |
| NCT02294344 | Terminated | N/A | The Clinical Efficacy of DFPP in Patients With AAGN | June 2014 | April 2017 |
| NCT02198248 | Unknown status | Phase 4 | Low-dose Glucocorticoid Vasculitis Induction Study | October 2014 | June 2021 |
| NCT02180126 | Unknown status | Differing Levels of Positive Anti-Neutrophil Cytoplasm Antibody (ANCA) Test and Their Correlation With Vasculitis or Malignancy or Chronic Inflammation | August 2014 | January 2015 | |
| NCT01275287 | Withdrawn | Phase 2 | Targeting Complement Activation in Antineutrophil Cytoplasmic Autoantibodies (ANCA)-Vasculitis - Eculizumab | May 2011 | December 2012 |
| NCT01275274 | Withdrawn | Phase 2 | Retinoids in ANCA Small Vessel Vasculitis: Silencing Autoantigens | January 2012 | December 2013 |
- MeSH unique ID (MeSH (Medical Subject Headings))
- D056648